SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that data from 41 abstracts across its portfolio of Alzheimer’s disease pharmaceuticals and diagnostics will be presented at the 2022 Alzheimer’s Association International Conference (AAIC), which will be held in San Diego from July 31 - Aug. 4, 2022. Among the data are new presentations on Genentech’s investigational subcutaneous anti-amyloid monoclonal antibody gantenerumab and the Elecsys® Amyloid Plasma Panel. Additionally, detailed results from the Alzheimer’s Prevention Initiative Autosomal Dominant Alzheimer's Disease (API ADAD) Trial evaluating the investigational monoclonal antibody crenezumab will be presented to inform future Alzheimer’s prevention research.
“Following the science represents the foundation of our company. Our work in Alzheimer’s over the past 20 years has helped transform disease understanding and ongoing approaches to clinical research,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. “We are pleased to bring a strong scientific presence to this year’s meeting, and we look forward to sharing our learnings in Alzheimer’s biology, diagnosis and treatment with the broader community.”
Gantenerumab Data Underscore Long-Term Commitment to Advancing Alzheimer’s Therapeutic Research
The history of the gantenerumab clinical development will be presented during an AAIC Scientific Session on Wednesday, Aug. 3 at 8:00 a.m. PT. This will include:
- How the needs of people living with Alzheimer's disease informed the design of current gantenerumab clinical studies and key learnings regarding treatment exposure, target population, enrichment strategies and ARIA management.
- Future development plans, including opportunities to offer greater flexibility of treatment administration to meet the needs of people living with Alzheimer’s.
- Opportunities to address barriers to inclusive research and equitable access.
The Phase III GRADUATE program in early Alzheimer’s disease includes two global, double-blind, randomized, placebo-controlled clinical trials, GRADUATE I and II. Data will be available in Q4, 2022; topline results will be presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference on Wednesday, Nov. 30, 2022.
Crenezumab Data Advance Understanding of Prevention Efforts for Autosomal Dominant Alzheimer’s
Detailed results from the Phase II Alzheimer’s Prevention Initiative Autosomal Dominant Alzheimer's Disease (API ADAD) Trial will be presented. The trial did not demonstrate a statistically significant clinical benefit in either of its co-primary endpoints, evaluating the ability of crenezumab to slow or prevent Alzheimer’s disease in people with a specific genetic mutation after five to eight years of treatment compared with placebo. Data will be featured in the AAIC News Briefing on Tuesday, Aug. 2 at 7:00 a.m. PT followed by a Scientific Session at 8:00 a.m. PT. Researchers will discuss the trial’s design, clinical outcomes, brain imaging and cerebrospinal fluid (CSF) biomarker findings.
Diagnostics Continues to Drive Innovation in Improving Timely Diagnosis of Alzheimer’s
Study results leading to the selection of blood-based biomarkers used in the Roche Diagnostics Elecsys Amyloid Plasma Panel, a test with the potential to aid in the detection of people with amyloid pathology, will be presented on Tuesday, Aug. 2. The Elecsys Amyloid Plasma Panel, which was recently granted FDA Breakthrough Device Designation, has the potential to better direct people towards a confirmatory Alzheimer’s diagnosis, either with amyloid positron emission tomography (PET) or cerebrospinal fluid (CSF) testing, where appropriate.
Data Presentations Across Genentech’s Alzheimer’s Disease Portfolio
Investigational Medicine and/or Diagnostics |
Abstract Title |
Presentation Number (type), Session Title
Presentation Date + Time (PT) |
Gantenerumab |
Open RoAD: Design and baseline characteristics of an open-label rollover study evaluating long-term safety and tolerability of subcutaneous gantenerumab in participants with early Alzheimer’s disease |
In-Person Poster
Sunday, July 31 7:00 a.m. - 11:55 p.m. |
Linking amyloid to clinical outcome: A quantitative semi-mechanistic model based on the A/T/N biomarker framework to simulate the natural history of Alzheimer’s disease and the effects of anti-amyloid treatment. |
In-Person Poster
Sunday, July 31 7:00 a.m. - 11:55 p.m. |
|
Using an external control to contextualize efficacy data from patients with prodromal and mild Alzheimer’s disease treated with gantenerumab in SCarlet RoAD and Marguerite RoAD open-label extension studies |
Hybrid Oral Session
Sunday, July 31 3:05 p.m. - 3:15 p.m. |
|
Baseline participant characteristics of GRADUATION: a study to evaluate once-weekly subcutaneous administration of gantenerumab |
Virtual Only Poster
Sunday, July 31 7:00 a.m. - 11:55 p.m. |
|
Mortality across the Alzheimer's disease clinical stages: an analysis using the U.S. National Alzheimer’s Coordinating Center Uniform Data Set |
Virtual Only Poster
Sunday, July 31 7:00 a.m. - 11:55 p.m. |
|
Allowing “rescue therapy” in preclinical Alzheimer’s trials |
In-Person Poster
Tuesday, Aug. 2 12:00 a.m. - 11:59 p.m. |
|
The clinical development history of gantenerumab‚ a subcutaneous anti-Aβ monoclonal antibody for early Alzheimer’s disease: Building on lessons from the past and paving a path for the future |
Hybrid Focussed Topic Session
Wednesday, Aug. 3 8:00 a.m. - 8:45 a.m. |
|
Gantenerumab treatment increases plasma beta-amyloid (1–42) and decreases plasma ptau |
In-Person Poster
Wednesday, Aug. 3 12:00 a.m. - 11:59 p.m. |
|
Blood-based biomarker pre-screening in the SKYLINE secondary prevention study with gantenerumab |
In-Person Poster
Wednesday, Aug. 3 12:00 a.m. - 11:59 p.m. |
|
Determining the amyloid PET and CSF inclusion criteria for the SKYLINE secondary prevention study with gantenerumab |
In-Person Poster
Wednesday, Aug. 3 12:00 a.m. - 11:59 p.m. |
|
Comparing ARIA-E severity scales and effects of treatment management thresholds |
In-Person Poster
Wednesday, Aug. 3 12:00 a.m. - 11:59 p.m. |
|
Crenezumab |
Electrocardiogram differences in cognitively unimpaired PSEN1-E280A carriers and non-carriers from the Alzheimer’s Prevention Initiative Autosomal-Dominant Alzheimer’s Disease Colombia trial |
Virtual Only Poster
Sunday, July 31 7:00 a.m. - 11:55 p.m. |
Longitudinal lumbar puncture tolerability and adherence in the Alzheimer’s Prevention Initiative Autosomal-Dominant Alzheimer’s Disease Colombia Trial |
Virtual Only Poster
Sunday, July 31 7:00 a.m. - 11:55 p.m. |
|
Age at menarche and relationship to baseline brain imaging and cognitive measurements related to PSEN1 E280A mutation from the API ADAD Trial |
Poster
Wednesday, Aug. 3 12:00 a.m. - 11:59 p.m. |
|
API ADAD Colombia Trial initial findings: a randomized, double-blind, placebo-controlled, parallel-group study in cognitively unimpaired PSEN1 E280A mutation carriers evaluating efficacy and safety of crenezumab |
Featured Topic Session
Tuesday, Aug. 2 8:00 a.m. - 8:45 a.m. |
|
Clinical Profiles of Persons Who Progress to Cognitive Impairment in the Alzheimer’s Prevention Initiative (API) ADAD Colombia Trial |
In-Person Poster
Sunday, July 31 9:00 a.m. - 4:15 p.m. |
|
Semorinemab |
In vivo head-to-head comparison of [18f]GTP1 and [18f]PI2620 in Alzheimer’s disease |
In-Person Poster
Saturday, July 30 12:25 p.m. - 1:40 p.m. |
Prognostic utility of baseline [18F]GTP1 tau PET signal for subsequent cognitive and functional decline in prodromal-to-mild Alzheimer’s disease |
In-Person Poster
Saturday, July 30 12:25 p.m. - 1:40 p.m. |
|
Evaluation of longitudinal [18F]GTP1 tau burden metrics in the Tauriel Phase II study |
Hybrid Oral Session
Sunday, July 31 11:35 a.m. - 11:45 a.m. |
|
Characterizing progressive speech changes in prodromal-to-mild Alzheimer’s disease using natural language processing |
In-Person Poster
Sunday, July 31 12:00 a.m. - 11:59 p.m. |
|
Selecting appropriate meaningful change thresholds for trials of early (prodromal-to-mild) AD: A caregiver-rated, anchor-based analysis based on the Tauriel Study |
Virtual Oral Session
Monday, Aug. 1 12:05 p.m. - 12:15 p.m. |
|
Diagnostics |
Current diagnostic pathways for Alzheimer's Disease - a comparison of six countries |
In-Person Poster
Sunday, July 31 7:00 a.m. - 11:55 p.m.
|
Improving statistical modeling with a neuropathology-Based APOE Genetic Risk Score |
Virtual Only Poster
Sunday, July 31 7:00 a.m. - 11:55 p.m. |
|
Cerebrospinal fluid soluble TREM2 is associated with accelerated AD-related longitudinal neurodegeneration in preclinical Alzheimer’s disease |
Virtual Only poster
Sunday, July 31 7:00 a.m. - 11:55 p.m.
|
|
Best combination of CSF biomarkers for predicting cognitive decline and clinical progression: A multi-cohort study |
Virtual Oral Session
Sunday, July 31 9:15 a.m. – 9:25 a.m.
|
|
Second-generation fully automated Elecsys cerebrospinal fluid immunoassays demonstrate high precision, reproducibility, and sample stability suitable for clinical routine |
In-Person Poster
Monday, Aug. 1 12:00 a.m. - 11:59 p.m. |
|
Modifying effect of AD pathology in the association between CSF synaptic biomarkers and brain function and structure in preclinical Alzheimer |
Virtual Lightning Presentation Round
Monday, Aug. 1 8:00 a.m. - 8:04 a.m. |
|
Air pollution has a more deleterious effect on Alzheimer’s disease biomarkers in genetic predisposition to larger hippocampal volumes |
Virtual Oral Session
Monday, Aug. 1 3:03 p.m. - 3:15 p.m. |
|
Associations between semantic memory for proper names in story recall and CSF amyloid and tau in a cognitively unimpaired sample |
In-Person Poster
Monday, Aug. 1 12:00 a.m. - 11:59 p.m. |
|
Sex differences in CSF biomarkers profile of accelerated biological aging individuals at risk of AD |
In-Person Poster
Monday, Aug. 1 12:00 a.m. - 11:59 p.m. |
|
Impact of CSF pTau/Aβ42 on brain structure and metabolism in middle-aged cognitively unimpaired individuals |
In-Person Poster
Tuesday, Aug. 2 12:00 a.m. - 11:59 p.m. |
|
Clinical performance and robustness of blood-based biomarkers for early detection of amyloid pathology associated with Alzheimer’s disease |
In-Person Poster
Tuesday, Aug. 2 12:00 a.m. - 11:59 p.m. |
|
Predicting CSF neurogranin and neurofilament light chain protein levels with a neuropathology-based APOE genetic risk score |
In-Person Poster
Tuesday, Aug. 2 12:00 a.m. - 11:59 p.m. |
|
Impact of pre-analytical factors on blood-based biomarkers of Alzheimer’s disease |
In-Person Poster
Tuesday, Aug. 2 12:00 a.m. - 11:59 p.m. |
|
The effects of stressful life events on Alzheimer’s disease biomarkers, neuroinflammation and brain integrity in later life: a life course perspective |
Hybrid Lightning Presentation Round
Wednesday, Aug. 3 8:08 a.m. - 8:12 a.m. |
|
Gut microbe-modulated metabolites are longitudinally associated with higher neurodegeneration biomarkers in cerebrospinal fluid (CSF) |
Hybrid Oral Session
Wednesday, Aug. 3 2:45 p.m. - 2:55 p.m. |
|
Structural and metabolic brain correlates of excess Aβ accumulation at the earliest AD continuum |
In-Person Poster
Wednesday, Aug. 3 12:00 a.m. - 11:59 p.m. |
|
Biological brain age prediction using machine learning on structural neuroimaging data: multi-cohort validation against biomarkers of Alzheimer’s disease and neurodegeneration |
In-Person Poster
Wednesday, Aug. 3 12:00 a.m. - 11:59 p.m. |
|
Roadmap to implementation of a fully automated blood-based biomarker test to facilitate diagnosis and treatment in early Alzheimer’s disease |
In-Person Poster
Wednesday, Aug. 3 12:00 a.m. - 11:59 p.m.
|
|
Becoming physically active or maintaining activity during midlife is associated with biomarkers of amyloid-beta, microglia, and temporal lobe integrity |
Hybrid Oral Session
Thursday, Aug. 4 10:05 a.m. - 10:15 a.m. |
About Genentech in Alzheimer’s disease
With more than two decades of scientific research in Alzheimer’s, Genentech and Roche are working towards a day when we can detect the disease early and stop its progression to preserve what makes people who they are. Today, the companies’ Alzheimer’s portfolio spans investigational medicines for different targets, types and stages of the disease. It also includes diagnostic tools, including digital, blood-based and cerebrospinal fluid (CSF) tests, aiming to more effectively detect, diagnose, and monitor the disease. Yet the challenges of Alzheimer’s go well beyond the capabilities of science, and making a meaningful impact requires collaboration both within the Alzheimer’s community and outside of healthcare. Genentech and Roche will continue to work together with numerous partners with the hope of transforming millions of lives.
About Gantenerumab
Gantenerumab is a fully-human monoclonal IgG1 antibody, an investigational medicine that is subcutaneously administered and designed to target and bind to aggregated forms of beta-amyloid and activate immune cells in the brain (microglia) to clear amyloid plaques and prevent further accumulation.
Gantenerumab is currently being investigated in eight clinical trials, including:
- GRADUATE I and II, two Phase III studies investigating the efficacy and safety of gantenerumab compared with placebo in up to 1,000 participants per study who have early Alzheimer’s over 27 months. Results are expected in Q4, 2022.
- GRADUATION, an open-label study to evaluate the pharmacodynamic effects of once weekly administration in participants with early Alzheimer’s disease.
- Post-GRADUATE, a rollover open-label study for GRADUATE I and II to continue assessing the efficacy and safety of gantenerumab in participants with early Alzheimer’s disease.
- Open RoAD, a rollover open-label study for the former SCarlet RoAD and Marguerite RoAD OLEs to continue to evaluate the safety and tolerability of long-term administration of gantenerumab in participants with Alzheimer’s disease.
- DIAN-TU-002 Primary Prevention, an investigator-initiated study evaluating whether Alzheimer’s can be prevented in people with a genetic predisposition to developing rare, early-onset forms of the disease called Autosomal Dominant AD (ADAD). Unlike most Alzheimer’s disease prevention studies, it enrolls people up to 25 years before the disease has started in the brain.
- DIAN-TU-001 OLE, an exploratory extension study in people with ADAD who presented with or were close to the expected symptoms of Alzheimer’s disease at baseline of the double-blind study, aiming to further investigate the relationship of biomarker changes with cognitive and clinical findings.
- SKYLINE, a Phase III secondary prevention trial to evaluate the efficacy and safety of gantenerumab in participants at risk for or at the earliest stages of Alzheimer's disease.
About Crenezumab
Crenezumab is an investigational, monoclonal antibody designed to neutralize neurotoxic oligomers, a form of beta-amyloid. Crenezumab has an antibody backbone (IgG4) designed to minimize the inflammatory response in the brain, which may result in a lower risk of certain MRI (magnetic resonance imaging) abnormalities known as ARIA (Amyloid-Related Imaging Abnormalities). The investigational medicine is being developed by Genentech and is part of a collaboration with AC Immune SA.
About Semorinemab
Semorinemab is an investigational monoclonal anti-tau antibody that targets the N-terminal portion of the tau protein, and is designed to bind to tau and slow its spread between neurons. In tauopathies such as Alzheimer’s disease, tau misfolds and forms tangles, which cause cell damage and ultimately neuronal death. It is hypothesized that abnormal tau protein then spreads between neurons, gradually involving more areas of the brain, and leading to clinical disease progression. Tau-targeting antibody therapies are designed to slow or stop this process of tau spread. The investigational medicine is being developed by Genentech and is part of a collaboration with AC Immune SA.
About the Roche Diagnostics Elecsys® Amyloid Plasma Panel
The Elecsys Amyloid Plasma Panel measures phosphorylated Tau (pTau) 181 protein assay and apolipoprotein (APOE) E4 assay in human blood plasma. Elevations in pTau occur in early stages of Alzheimer’s, while the presence of APOE E4 constitutes the most common genetic risk factor for Alzheimer’s disease. The result is intended for consideration in conjunction with other clinical information to advise physicians on whether there is a need for further confirmatory testing for Alzheimer’s disease with amyloid positron emission tomography (PET) or cerebrospinal fluid (CSF) testing. Patients testing negative with the Elecsys Amyloid Plasma Panel are unlikely to be amyloid positive and should be investigated for other causes of cognitive decline.
About Genentech in Neuroscience
Neuroscience is a major focus of research and development at Genentech and Roche. Our goal is to pursue groundbreaking science to develop new treatments that help improve the lives of people with chronic and potentially devastating diseases.
Genentech and Roche are investigating more than a dozen medicines for neurological disorders, including multiple sclerosis, stroke, Alzheimer’s disease, Parkinson’s disease and autism spectrum disorder. Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neuroscience today.
About Genentech
Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.
